ALN-APP
ALN-APP-001
Phase 1 small_molecule active
Quick answer
ALN-APP for Early-Onset Alzheimer Disease is a Phase 1 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- Early-Onset Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active